Ionis Posts $243 Million in Q3 Revenue and $0.66 Per-Share Loss

Ionis Pharmaceuticals recorded $243 million in revenue and a net loss per share of $0.66 under generally accepted accounting principles (GAAP) for Q3 2026, which ended Sept. 30. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.